Combination of BTK inhibitor orelabrutinib, anti-CD19 antibody tafasitamab, and IMiD lenalidomide for the treatment of B cell malignancies-MedSci.cn

Combination of BTK inhibitor orelabrutinib, anti-CD19 antibody tafasitamab, and IMiD lenalidomide for the treatment of B cell malignancies

Zhang, HJ; Liang, RX; Xu, HP; Li, XR; Zhao, RB; Bin Zhang, J; Ouyang, DX

CANCER RESEARCH, 2023; 83 (7):

科室
- - 订阅+
  - 更多科室
工具
服务